ABTNEUTRAL

Revenue Growth (YoY)

7.8%

Higher than 56% of Healthcare sector peers

Updated 1927h ago

Sector Performance

56th percentile

ABT

7.8%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Abbott Laboratories’ current revenue growth of 7.8% year-over-year (YoY) means the company increased its sales by that percentage compared to the same quarter a year ago, a basic measure of top-line expansion.

This sits above the healthcare sector median of 7.0%, placing Abbott in the 59th percentile among its peers—above average but not at the top of the sector. The metric has been perfectly stable over the last eight quarters, with a YoY change of +0.0% and a quarter-over-quarter change of +0.0%, meaning growth has held exactly constant. A stable level of growth that modestly exceeds the sector median implies limited risk from revenue volatility, but also no clear catalyst for acceleration or deceleration. This combination of a solid but unremarkable growth rate and a flat trend aligns with a neutral outlook—neither strongly bullish nor bearish. The metric therefore directly supports the overall NEUTRAL verdict, as it shows consistent performance without signaling an opportunity or a concern.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about ABT?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does ABT's Revenue Growth (YoY) compare to its sector?

ABT's Revenue Growth (YoY) of 7.8% compares to a Healthcare sector median of 6.2%, placing it in the 56th percentile.

Who are ABT's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ZBH (9.3%), A (10.0%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.